“This is an incredibly exciting time at Achieve, as we remain steadfastly focused on advancing cytisinicline to address the urgent need for effective smoking and vaping cessation solutions,” stated Rick Stewart, Chief Executive Officer of Achieve. “With increased attention at the regulatory level and in the media on nicotine dependence, coupled with the lack of innovation in this field for over 20 years, we are committed to bringing the first new prescription therapy to market. We remain on track for our planned NDA submission in the second quarter of 2025 and are driven by the potential to make a meaningful difference in public health.”
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHV:
- Achieve Life Sciences files to sell 3.49M shares of common stock for holders
- ACHV Upcoming Earnings Report: What to Expect?
- Achieve Life Sciences CMO speaks at FDA, NIH Smoking Cessation Public Meeting
- Achieve Life Sciences promotes Xinos to Chief Commercial Officer
- Achieve Life Sciences announces completion of enrollment in ORCA-OL trial